Scarica l'app Stockscreener
1.10
0.00%
0.00
Dopo l'orario di chiusura:
1.10
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - moomoo.com
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
What is HC Wainwright's Estimate for MIST FY2028 Earnings? - MarketBeat
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals Q2 Results: Net loss widens to $28.6M - scanx.trade
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction - Investing.com
Q2 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals shares tumble after Q2 earnings miss - Yahoo Finance
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August - Investing.com India
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals reports Q2 2026: $0.6M product revenue, $28.6M net loss, $170.6M cash - TradingView
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss - Investing.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Milestone Pharmaceuticals Inc. Q2 2026: Revenue $0.6M, EPS $(0.21) — 10-Q Summary - TradingView
Press Release: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
What To Expect From Milestone Pharmaceuticals Inc (MIST) Q2 2026 Earnings - Yahoo Finance
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Milestone Pharmaceuticals (MIST): Pavaki Capital group reports 7.3% ownership stake - Stock Titan
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Wednesday - MarketBeat
Milestone Pharmaceuticals sets Aug. 12, 8:30 a.m. webcast - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST) - Yahoo Finance
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Cash Flow - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MIST|Milestone Pharmaceuticals Inc|Price:1.100|Chg%:+0.030 - TradingKey
TradingKey - TradingKey
MIST|Milestone Pharmaceuticals Inc|Price:1.160|Chg%:-0.040 - TradingKey
Milestone Pharmaceuticals (MIST) Declines 3.33% as Stock Tests Key Support at $1.10Median Line - dars.gov.et
Milestone Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Milestone Pharmaceuticals (MIST) Q4 2024 earnings summary - Quartr
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular PsoriasisA Milestone Recognition of GPP as a Distinct Rare Disease in Europe - PR Newswire
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision - TMX Newsfile
Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Upgraded by Zacks Research - MarketBeat
Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals (MIST) Faces Downward Pressure Near Key SupportParabolic SAR - po-news-eg.net
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - AOL.com
Milestone Pharmaceuticals (MIST) Slips 2.3% as Shares Test Key Support LevelsBuy Signal Reports - DonanımHaber
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone lures six new employees with 288,000 options - Stock Titan
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Enterprise value to EBITDA forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to earnings forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST) - TradingView
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):